Predictive glycoengineering of biosimilars using a Markov chain glycosylation model

Biotechnology Journal

Volumn 12, Issue 2, 2017, Pages

  Spahn, Philipp N ^a,b   Hansen, Anders H ^b   Kol, Stefan ^b   Voldborg, Bjørn G ^b   Lewis, Nathan E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Chalmers University of Technology   (Denmark)

Author keywords

Biosimilars; CHO cells; Erythropoietin; Glycoengineering; Markov model

Indexed keywords

CELL CULTURE; CLONE CELLS; CLONING; GENETIC ALGORITHMS; MARKOV PROCESSES; REACTION RATES;

BIOSIMILARS; CHO CELL; ERYTHROPOIETIN (EPO); GLYCOENGINEERING; MARKOV MODEL;

GLYCOSYLATION;

BIOSIMILAR AGENT; ERYTHROPOIETIN; GLYCOSYLTRANSFERASE; IMMUNOGLOBULIN G; RITUXIMAB;

ARTICLE; BIOENGINEERING; GENE INACTIVATION; GENETIC ALGORITHM; GLYCOENGINEERING; GLYCOSYLATION; MARKOV CHAIN; MOLECULAR CLONING; PRIORITY JOURNAL; SIMULATION; ANIMAL; BIOTECHNOLOGY; CHO CELL LINE; CRICETULUS; METABOLISM; PROCEDURES;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; BIOTECHNOLOGY; CHO CELLS; CRICETULUS; GLYCOSYLATION; MARKOV CHAINS;

EID: 85007483284     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201600489     Document Type: Article

References (44)

1. Griebenow, K. A. I., Sola, R. J., Effects of glycosylation on the stability of protein pharmaceuticals. J. Pharm. Sci. 2009, 98, 1223–1245.
2. Solá, R. J., Griebenow, K., Glycosylation of therapeutic proteins: An effective strategy to optimiza efficacy. BioDrugs 2011, 24, 9–21.
3. Raju, T. S., Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 2008, 20, 471–478.
4. Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., Dwek, R. A., Emerging principles for the therapeutic exploitation of glycosylation. Science 2014, 343, 1235681.
5. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev. Drug Discovery 2009, 8, 226–234.
6. Li, H., d'Anjou, M., Pharmacological significance of glycosylation in therapeutic proteins. Curr. Opin. Biotechnol. 2009, 20, 678–684.
7. Zhang, P., Woen, S., Wang, T., Liau, B. et al., Challenges of glycosylation analysis and control: An integrated approach to producing optimal and consistent therapeutic drugs. Drug Discovery Today 2016, 21, 740–765.
8. Tsuruta, L. R., Lopes dos Santos, M. Moro, A. M., Biosimilar advancements: Moving on to the future. Biotechnol. Prog. 2015, 31, 1139–1149.
9. Niwa, R., Satoh, M., The current status and prospects of antibody engineering for therapeutic use: Focus on glycoengineering technology. J. Pharm. Sci. 2015, 104, 930–941.
10. Chiang, A. W., Li, S., Spahn, P. N., Richelle, A. et al., Modulating carbohydrate–protein interactions through glycoengineering of monoclonal antibodies to impact cancer physiology. Curr. Opin. Struct. Biol. 2016, 40, 104–111.
11. Spahn, P. N., Hansen, A. H., Hansen, H. G. Arnsdorf, J. et al., A Markov chain model for N-linked protein glycosylation – towards a low-parameter tool for model-driven glycoengineering. Metab. Eng. 2016, 33, 52–66.
12. Spahn, P. N., Lewis, N. E., Systems glycobiology for glycoengineering. Curr. Opin. Biotechnol. 2014, 30, 218–224.
13. Villiger, T. K., Roulet, A., Périlleux, A., Stettler, M. et al., Controlling the time evolution of mAb N-linked glycosylation – Part I: Micro-bioreactor experiments. Biotechnol. Progr. 2016, 32, 1135–1148.
14. Grav, L. M., Lee, J. S., Gerling, S., Kallehauge, T. B. et al., One-step generation of triple knockout CHO cell lines using CRISPR Cas9 and fluorescent enrichment. Biotechnol. J. 2015, 10, 1446–1456.
15. Mitchell M. An Introduction to Genetic Algorithms. MIT Press 1998.
16. Visser, J., Feuerstein, I., Stangler, T., Schmiederer, T. et al., Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013, 27, 495–507.
17. Turner, M., Magic bullets to blockbusters. Nature 2015, 523, 34.
18. Daniel, M. G., Pawlik, T. M., Fader, A. N., Esnaola, N. F., Makary, M. A., The Orphan Drug Act. Am. J. Clin. Oncol. 2015, 39, 210–213.
19. Raju, T. S., Scallon, B., Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain. Biotechnol. Progr. 2007, 23, 964–971.
20. Yang, Z., Wang, S., Halim, A., Schulz, M. A. et al., Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat. Biotechnol, 2015, 33, 842–844.
21. Brühlman, D., Jordan, M., Hemberger, J., Sauer, M. et al., Tailoring recombinant protein quality by rational media design. Biotechnol. Progr. 2015, 31, 615–629.
22. Imai-Nishiya, H., Mori, K., Inoue, M., Wakitani. M. et al., Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: A new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol. 2007, 7, 84.
23. Rillahan, C. D., Antonopoulos, A., Lefort, C. T., Sonon, R. et al., Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol 2012, 8, 661–668.
24. Gardai, S., Epp, A., Linares, G., et al., SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities, in: AACR 106th Annual Meeting 2015. Cancer Res. 2015, 75, Abstract Nr. 2472, doi: 10.1158/1538-7445.AM2015-2472.
25. Okeley, N. M., Toki, B. E., Zhang, X., Jeffrey, S. C. et al., Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation. Bioconjugate Chem. 2013, 24, 1650–1655.
26. Surve, T., Gadgil, M. Manganese increases high mannose glycoform on monoclonal antibody expressed in CHO when glucose is absent or limiting: Implications for use of alternate sugars. Biotechnol. Progr. 2015, 31, 460–467.
27. Pande, S., Rahardjo, A., Livingston, B., Mujacic, M., Monensin, a small molecule ionophore, can be used to increase high mannose levels on monoclonal antibodies generated by Chinese hamster ovary production cell-lines. Biotechnol. Bioeng. 2015, 112, 1383–1394.
28. Villacres C, Tayi VS, Lattova E, Perreault, H., Butler, M., Low glucose depletes glycan precursors, reduces site occupancy and galactosylation of a monoclonal antibody in CHO culture. Biotechnol. J. 2015, 10, 1051–1066.
29. Kim, H., Kim, J. S., A guide to genome engineering with programmable nucleases. Nat Rev Genet 2014, 15, 321–334.
30. Gaj, T., Gersbach, C. A., Barbas, C. F., ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31, 397–405.
31. Lee, J. S., Grav, L. M., Lewis, N. E., Faustrup Kildegaard, H., CRISPR/Cas9-mediated genome engineering of CHO cell factories: Application and perspectives. Biotechnol. J. 2015, 10, 979–994.
32. Weikert, S., Papac, D., Briggs, J., Cowfer, D. et al., Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat. Biotechnol. 1999, 17, 1116–1121.
33. Lin, N., Mascarenhas, J., Sealover, N. R., George, H. J. et al., Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression. Biotechnol. Progr. 2015, 31, 334–346.
34. Zalatan, J. G., Lee, M. E., Almeida, R., Gilbert, L. A. et al., Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 2015, 160, 339–350.
35. Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F. et al., RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat. Methods 2013, 10, 973–976.
36. Weber, W., Rimann, M., Spielmann, M., Keller, B. et al., Gas-inducible transgene expression in mammalian cells and mice. Nat. Biotechnol. 2004, 22, 1440–1444.
37. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 1992, 89, 5547–5551.
38. Grainger RK, James DC. CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation. Biotechnol. Bioeng. 2013, 110, 2970–2983.
39. Gramer, M. J., Eckblad, J. J., Donahue, R., Brown, J. et al., Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng 2011, 108, 1591–1602.
40. St Amand, M. M., Radhakrishnan, D., Robinson, A. S., Ogunnaike, B. A., Identification of manipulated variables for a glycosylation control strategy. Biotechnol. Bioeng, 2014, 111, 1957–1970.
41. del Val, I. J., Fan, Y., Weilguny, D., Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework. Biotechnol. J. 2016, 11, 610–623.
42. Jedrzejewski, P. M., del Val, I. J., Constantinou, A., Dell, A. et al., Towards controlling the glycoform: A model framework linking extracellular metabolites to antibody glycosylation. Int. J. Mol. Sci. 2014, 15, 4492–4522.
43. Neelamegham, S., Liu, G., Systems glycobiology: Biochemical reaction networks regulating glycan structure and function. Glycobiology 2011, 21, 1541–1553.
44. Hossler P., Protein glycosylation control in mammalian cell culture: Past precedents and contemporary prospects, in: Hu, W. S., Zeng, A.-P. (Eds.), Genomics and Systems Biology of Mammalian Cell Culture, Vol. 127, Springer 2012, pp. 187–219.